Evaluation of aminoglycoside- and methicillin-resistant Staphylococcus aureus: phenotypic and genotypic insights from clinical specimens in Ardabil, Iran.

Background: Combination therapy including an aminoglycoside antibiotic and a cell-wall active agent is considered the most suitable option to treat invasive infections with methicillin-resistant Staphylococcus aureus (MRSA). Dual drug therapy enhances the effectiveness of treatment and reduces the risk of resistance development. This study aims to elucidate the phenotypic and molecular resistance to aminoglycosides and methicillin, and the molecular epidemiologic characteristics of S.